Eterna Therapeutics
ERNA
7 hedge funds and large institutions have $6.1M invested in Eterna Therapeutics in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
38% less capital invested
Capital invested by funds: $9.86M → $6.1M (-$3.76M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$8K |
| 2 |
Citigroup
New York
|
-$1K |
ERNA Hedge Fund Activity: Q3 2014 in Review
7 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2014, worth a combined $6.1M — down 38% from $9.86M a quarter earlier.
Fund positioning in ERNA was balanced in Q3 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Virtu KCG Holdings, cutting an estimated $8K.
- 7 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $6.1M of Eterna Therapeutics stock for Q3 2014, down 38% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q3 2014 and 0 closed out.
- The largest Eterna Therapeutics seller in Q3 2014 was Virtu KCG Holdings, an estimated $8K sold.
Based on aggregated 13F filings for Q3 2014.